Nearly 30 drug makers will raise the prices of their medicines in January after a temporary halt to increases; more than 180,000 Virginians without insurance coverage will now have access to Medicaid coverage under the program’s expansion; despite lagging far behind 2017's enrollment numbers for most of open enrollment, the number of people who signed up for Affordable Care Act plans on HealthCare.gov was only down 4% after a surge of sign-ups last week.
Nearly 30 drug makers will raise the prices of their medicines in January after a temporary halt to increases. Reuters reported that some of the companies expected to increase prices were Allergan Plc, GlaxoSmithKline Plc, Amgen Inc, and Novartis AG. After criticisms from President Donald Trump, many drug makers had decided to pause drug price hikes. In California, where a new state law requires companies notify payers if they intend double-digit percentage increases over 2 years, 28 drug makers filed notifications for price increases.
More than 180,000 Virginians without insurance coverage will now have Medicaid coverage under the program’s expansion. The state General Assembly expanded Medicaid to cover people earning up to 138% of the federal poverty line, which made an additional 400,000 people eligible for Medicaid, according to the Richmond Times-Dispatch. Virginia’s Department of Medical Assistance Services expects 360,000 people to have enrolled by the end of 2019.
Throughout open enrollment, the number of people signing up for Affordable Care Act plans on HealthCare.gov had lagged behind 2017. However, after a surge of sign-ups in the last week, enrollment is now only down 4% compared with the same point last year, reported The New York Times. In the last week of enrollment, 4.3 million people signed up, which surpassed the 4.1 million who signed up in the last week of 2017. CMS Administrator Seema Verma suggested that the low unemployment rate may have contributed to the drop since more Americans likely have employer-based coverage. The number of sign-ups increased in 5 states: Florida, Hawaii, Mississippi, Oklahoma, and Wyoming.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More